City Therapeutics Raises $99.5M Series B as Investors Double Down on the Future of RNAi
City Therapeutics, a Cambridge, Massachusetts-based biotechnology company focused on RNA interference (RNAi) therapeutics, has raised $99.5M in Series B funding. The round was led by Viking Global Investors and Sofinnova Investments, with participation from new investors Casdin Capital and NYBC Ventures, alongside returning backers including ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Ventures.
The financing brings City Therapeutics' total disclosed funding to $234.5M, following the company's $135M Series A launch financing in 2024. The funding matters because it reflects growing investor conviction that the next chapter of RNAi will be defined not by proving the science works, but by solving where RNAi medicines can go and how effectively they can get there.
For the broader biotechnology market, the round signals continued appetite for platform companies attempting to expand RNAi beyond its traditional strengths and into new therapeutic territories. In a funding environment that has become increasingly selective, investor enthusiasm around RNAi delivery and platform innovation remains very much alive.
What Happened
City Therapeutics announced a $99.5M Series B financing to advance its next-generation RNAi platform and pipeline. According to the company's official funding announcement, the financing will support advancement of its RNAi platform and therapeutic programs. The company is developing RNAi-based medicines built around engineered siRNA trigger molecules and targeted delivery technologies designed to improve potency, specificity, durability, and tissue reach.
The investor list is notable for both its depth and composition. Viking Global Investors and Sofinnova Investments led the round, while Casdin Capital and NYBC Ventures joined as new investors. Existing investors returned with additional capital, including ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Ventures.
Biotechnology financing has become increasingly selective. Investors are no longer funding broad scientific ambitions without clear technical differentiation. Capital is concentrating around companies that possess strong platforms, experienced leadership teams, and a credible path toward clinical value creation, and City Therapeutics appears to check all three boxes.
Why This Matters
RNA interference, or RNAi, is a gene-silencing technology that uses small RNA molecules to selectively reduce disease-causing protein production. The science itself has already crossed an important threshold of validation, shifting the industry's attention toward a different challenge entirely.
The question is no longer whether RNAi can silence disease-causing genes. The question is whether developers can reliably deliver therapies to the right tissues, at the right doses, with the right durability and safety profile. Many scientific breakthroughs stall not because the biology is wrong, but because delivery becomes the gatekeeper between laboratory success and clinical impact.
City Therapeutics is betting that the next major wave of RNAi innovation will come from improving trigger design and delivery infrastructure rather than simply identifying new biological targets. For investors, that thesis appears compelling enough to support nearly a quarter-billion dollars in disclosed financing within less than 2 years of the company's public launch.
The Team Behind City Therapeutics
One reason investors continue to pay attention to City Therapeutics is the concentration of RNAi expertise surrounding the company. John Maraganore, PhD, Co-Founder and Executive Chair, is one of the most recognizable figures in the RNAi ecosystem after helping build Alnylam Pharmaceuticals into one of the category's defining companies.
Andy Orth, CEO, leads the company alongside Tracy Zimmermann, PhD, CSO; Sebastian Trousil, PhD, Co-Founder and COO; Ari Nowacek, MD, PhD, Co-Founder and SVP, Corporate Development; Baisong Mei, MD, PhD, CMO; and Anna O'Driscoll, Chief People Officer. The broader founding group includes Robert Nelsen, Mark Keating, MD, Kotaro Nakanishi, PhD, Yukihide Tomari, PhD, and Phillip Zamore, PhD.
In biotechnology, talent concentration often becomes a competitive advantage long before products reach the market. Scientific platforms can be replicated, but experience navigating clinical development, manufacturing complexity, regulatory hurdles, and capital markets is much harder to duplicate. That leadership density is part of the investment thesis.
Market Context
City Therapeutics is emerging from one of the world's most concentrated biotechnology ecosystems. Cambridge, Massachusetts remains home to leading biotech companies, academic institutions, venture investors, and life sciences infrastructure, creating a talent and capital network that continues to generate next-generation therapeutic platforms.
RNAi is entering a different phase of maturity. The first era focused on proving the modality could generate approved medicines. The next era is focused on expanding where those medicines can be deployed. Historically, RNAi has demonstrated particular strength in liver-targeted applications, but industry attention is increasingly shifting toward extrahepatic delivery opportunities and tissues that have proven more difficult to reach.
Viewed through a market lens, City Therapeutics is not merely developing individual drugs. The company has publicly highlighted ambitions across multiple tissue types and therapeutic areas, supported by proprietary approaches to trigger engineering and targeting. Investors frequently place higher strategic value on platforms capable of generating multiple future products than on companies dependent on a single clinical outcome.
Competitive Landscape
Competition within RNAi remains intense. Large public companies, emerging platform developers, and venture-backed startups are all pursuing new approaches to gene silencing, delivery technologies, and tissue targeting. What separates companies in this environment is increasingly less about participation in RNAi and more about technical differentiation.
City Therapeutics' disclosed pipeline provides an early glimpse into how the company intends to execute. CITY-FXI targets Factor XI with the goal of reducing thrombosis risk while minimizing bleeding complications, while CITY-RBP4 is being developed for Stargardt disease, an area with significant unmet medical need.
Different diseases and different biology sit underneath the same strategic thesis: better trigger design and smarter delivery can expand the practical reach of RNAi medicines and unlock opportunities that previous generations of technology struggled to address.
What This Signals
The investor mix is notable because it combines crossover capital, specialist healthcare investors, and venture firms with deep life sciences experience. That combination often reflects confidence not only in near-term programs but also in a platform's long-term strategic potential.
The funding environment remains challenging across much of venture-backed biotechnology, making rounds like this particularly informative. Investors are still writing large checks; they are simply doing so with greater precision. Capital is increasingly flowing toward technologies capable of generating multiple future products rather than isolated therapeutic bets.
The City Therapeutics financing suggests institutional investors continue to favor companies operating at the intersection of strong science, platform potential, and experienced leadership. That trend is becoming one of the defining characteristics of today's biotechnology funding landscape.
The Bigger Industry Shift
Every biotech cycle produces a handful of companies that become proxies for larger industry questions, and City Therapeutics is becoming one of those companies. The real question surrounding RNAi is no longer whether gene silencing works. The question is how broadly it can be applied across diseases, tissues, and therapeutic categories.
If RNAi can reliably reach more tissues, address more diseases, and maintain favorable therapeutic profiles, the market opportunity expands dramatically. That possibility explains why investors continue allocating meaningful capital to companies pursuing delivery innovation and next-generation platform technologies.
The $99.5M Series B is ultimately about more than a financing announcement. It is a signal that sophisticated investors believe the next meaningful advances in RNAi may come from improving the roads, not just choosing the destinations.
Frequently Asked Questions
What is City Therapeutics?
City Therapeutics is a Cambridge, Massachusetts-based biotechnology company developing RNA interference medicines using engineered siRNA trigger molecules and targeted delivery technologies.
How much funding has City Therapeutics raised?
City Therapeutics has raised $234.5M in disclosed funding, including a $135M Series A and a $99.5M Series B.
Who led the City Therapeutics Series B?
The $99.5M Series B was led by Viking Global Investors and Sofinnova Investments.
What is RNA interference (RNAi)?
RNA interference is a gene-silencing technology that uses small RNA molecules to reduce production of disease-causing proteins.
What diseases is City Therapeutics targeting?
City Therapeutics has publicly disclosed CITY-FXI, targeting Factor XI for thrombosis prevention, and CITY-RBP4, targeting Stargardt disease.
Where is City Therapeutics located?
City Therapeutics is headquartered in Cambridge, Massachusetts, one of the world's leading biotechnology hubs.
Why are investors interested in RNAi companies?
Investors view RNAi as a validated therapeutic modality with significant opportunities to expand into new tissues and disease categories through improved delivery technologies.
Why does this funding matter for biotechnology?
The financing signals continued investor confidence in platform-based biotechnology companies developing scalable therapeutic technologies capable of supporting multiple future products rather than a single-asset strategy.
